Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782609 | 0.81 | OPRK1 (0.48) | TSHRHSD17B10ALDH1A1MEN1KMT2A | |
| SCHEMBL28533997 | 0.78 | ALDH1A1 (0.46) | HSD17B10ALDH1A1KDM4ERXFP1OPRK1 | |
| SCHEMBL733159 | 0.75 | OPRK1 (0.49) | OPRK1 | |
| SCHEMBL28535766 | 0.75 | OPRK1 (0.48) | ALDH1A1MEN1KMT2AKDM4EOPRK1 | |
| SCHEMBL3601469 | 0.74 | CYP3A4 (0.50) | CYP3A4TSHRHSD17B10ALDH1A1GAA | |
| SCHEMBL9471700 | 0.74 | CYP3A4 (0.63) | CYP3A4TSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL1600624 | 0.73 | OPRK1 (0.42) | TSHRHSD17B10ALDH1A1OPRK1SMN1; SMN2 | |
| SCHEMBL10906862 | 0.73 | CYP3A4 (0.61) | CYP3A4TSHRHSD17B10ALDH1A1GAA | |
| SCHEMBL29225979 | 0.73 | CYP3A4 (0.61) | CYP3A4TSHRHSD17B10ALDH1A1GAA | |
| SCHEMBL30933424 | 0.73 | CYP3A4 (0.61) | CYP3A4TSHRHSD17B10ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2018-12-25 | — | — | US | disclosed |
| EP-3233867-B1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LTD (GB) | 2018-10-17 | — | — | EP | disclosed |
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | PULMOCIDE LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| EP-3233867-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | Pulmocide Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097761-A1 | 4,5-DIHYDRO-6H-THIENO[3,2-D]BENZAZEPINE DERIVATIVES AND THEIR USE TO TREAT RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS | PULMOCIDE LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160772-B2 | 5,6-dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | ZC3HAV1, DDX5, DPP4 | CYP3A4 293/4885TSHR 2685/4885HSD17B10 2497/4885 |
| US-20170355718-A1 | Novel 5,6-Dihydro-4H-benzo[b]thieno-[2,3-d]azepine derivatives | DDX5, ZC3HAV1, MAVS | CYP3A4 217/4885TSHR 2756/4885HSD17B10 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.